May 10 EpiPen maker Mylan NV said on Wednesday first-quarter profit more than quadrupled, as the maker of generic drugs benefited from strong demand outside the United States.
The company said net income rose to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents per share, a year earlier.
Revenue rose to $2.69 billion from $2.18 billion.
Mylan has been heavily criticized over steep price increases for EpiPen, its life-saving allergy shot, and also for classifying the treatment as a generic rather than a branded product, leading to smaller rebates to state Medicaid programs. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)
UPDATE 6-BA cancels flights from London as global IT outage causes chaos
* BA latest to be hit by computer problems (Adds comment by BA's chief executive)
GM says ISS advises against Greenlight share plan, board nominees
May 27 General Motors Co said on Saturday that proxy advisory firm Institutional Shareholder Services has recommended that shareholders vote against a slate of directors proposed by hedge fund Greenlight Capital and reject the hedge fund's plan to divide GM shares into two classes.